LH — Labcorp Holdings Inc.

Labcorp Holdings Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $3.5 billion, up 6% year-over-year.
• Adjusted Earnings Per Share (EPS): $4.25, an increase of 10.6%.
• Adjusted Operating Margin: Expanded by over 30 basis points to 14.4%.
• Free Cash Flow: $71 million, a significant improvement from a cash use of $108 million in the previous year.
• Segment Performance:
  • Diagnostics Revenue: Increased by 5%, totaling $2.8 billion.
  • Biopharma Laboratory Services (BLS) Revenue: Grew by 8.2% to $781 million, with Central Labs showing strong growth of 11%.

2. Strategic Updates and Business Highlights

• Labcorp is focusing on partnerships with health systems and local laboratories to expand its network and access to specialty diagnostics.
• Notable partnerships include a collaboration with Children's Hospital of Philadelphia and the acquisition of Crouse Health's laboratory assets.
• Specialty testing areas such as oncology and neurology are key growth drivers, with double-digit growth reported in these segments.
• Labcorp OnDemand continues to grow, launching new tests and a mobile app, MyLabcorp, aimed at enhancing consumer engagement.
• The company is investing in advanced technologies, including AI and robotics, to improve operational efficiency and customer experience.

3. Forward Guidance and Outlook

• Revenue Guidance: Expected to grow between 5% and 6.1% for the full year 2026, with Diagnostics segment growth projected at 5.1% to 5.9%.
• Adjusted EPS Guidance: Updated range is $17.70 to $18.35, reflecting a midpoint growth of approximately 10%.
• Free Cash Flow Guidance: Expected to be between $1.24 billion and $1.36 billion, with a focus on the second half of the year.
• The company anticipates continued margin expansion across both Diagnostics and BLS segments.

4. Bad News, Challenges, or Points of Concern

• Weather Impact: Estimated to have negatively affected revenue by approximately $15 million in Q1, primarily impacting the Diagnostics business.
• ACA Exchange Volumes: While initial enrollment is better than expected, the company remains cautious about the actual testing utilization by insured groups, maintaining a potential 30 basis point headwind for the year.
• Regulatory Risks: The CRUSH initiative by CMS aims to reduce fraud and waste in the lab industry, which could have implications for Labcorp if not managed carefully.
• Volume Constraints: Adverse weather and other factors have constrained organic volume growth, which could impact future performance.

5. Notable Q&A Insights

• Volume Growth: Management indicated that organic volume growth would have been higher without weather impacts, and they expect to recapture a significant portion of canceled appointments.
• Bookings Trends: The BLS segment is seeing strong growth, particularly in Central Labs, with a healthy trailing 12-month book-to-bill ratio of 1.04.
• Consumer Testing Environment: Labcorp is committed to investing in consumer health initiatives, with expectations for continued double-digit growth in Labcorp OnDemand.
• PAMA and RESULTS Act: Management is actively monitoring the PAMA survey and advocating for the RESULTS Act, which could significantly impact future reimbursement and operational dynamics.

Overall, Labcorp reported a strong start to 2026, with solid financial performance and strategic initiatives aimed at long-term growth, despite facing some challenges related to weather impacts and regulatory changes.